VORVor Biopharma Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+13% of shares).
Choppy, but holding above its 200-day average. Price is +6% vs its 200-day average.
Heavily shorted, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How VOR is trading
Vor Biopharma Inc. is −31% over the past year while the S&P 500 is +16%: 47 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +6.2%
vs 200-day average · close to trend
- RSI (14)
- 47
RSI (14) · neutral
- Below its 52-week high
- 35%
Below its 52-week high
Details›
- Last close2026-10-23
- $18.24
- 1 monthS&P 500 −0.94%
- −1.1%
- 1 yearS&P 500 +16%
- −31%
- 5 yearsS&P 500 +86%
- −94%
- vs 50-day average$21.08
- −13%
- 52-week high
- $28.13
- 52-week low
- $6.86
- Annualised volatility
- 151%
| Year | Return |
|---|---|
| 2026 (year to date) | +39% |
| 2025 | −41% |
| 2024 | −51% |
| 2023 | −66% |
| 2022 | −43% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 2 of 5 | −4.0% |
| Feb | 5 | 3 of 5 | +2.0% |
| Mar | 6 | 2 of 6 | −9.3% |
| Apr | 6 | 0 of 6 | −18% |
| May | 6 | 2 of 6 | −22% |
| Jun | 6 | 3 of 6 | +113% |
| Jul | 6 | 2 of 6 | −1.1% |
| Aug | 6 | 3 of 6 | +1.1% |
| Sep | 6 | 2 of 6 | −7.0% |
| Oct | 6 | 3 of 6 | −4.6% |
| Nov | 5 | 1 of 5 | −19% |
| Dec | 5 | 5 of 5 | +31% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.